Grégoire Le Gal, Michael J Kovacs, Marc Carrier, Kimberley Do, Susan R Kahn, Philip S Wells, David A Anderson, Isabelle Chagnon, Susan Solymoss, Mark Crowther, Marc Righini, Karine Lacut, Richard H White, Linda Vickars, Marc Rodger
The use of exogenous oestrogen in women with otherwise unprovoked venous thromboembolism (VTE) could be considered sufficient explanation to classify VTE as provoked if the risk of recurrent VTE after 3-6 months of anticoagulant treatment is similar to the risk of recurrent VTE observed after a surgery or prolonged immobilisation. Our objective was to assess the risk of recurrent VTE in women after a first unprovoked episode on oestrogen. The REVERSE study is a cohort study of patients with a first unprovoked VTE treated with anticoagulant treatment for 5-7 months...
September 2010: Thrombosis and Haemostasis